Biotechnology News 
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 7.
Pharma exports to touch $ 25 bn by 2014-15
Amid global economic concerns, the pharma exports are expected to reach $ 25 billion by 2014-15, a senior government official said.
Source: The Economic Times Healthcare and Biotech News - November 21, 2012 Category: Pharmaceuticals Source Type: news
Pharma Technology Focus - Issue 19
Research & Development Issue: In this issue we find out why small biotech companies take the innovative edge in new drug development, check out the new push for Alzheimer’s research, the search for a better TB treatment and new schizophrenia discover…
Source: Pharmaceutical Technology - November 21, 2012 Category: Pharmaceuticals Source Type: news
Cipla to buy control of S Africa's Cipla Medpro
Cipla plans to offer $215 million for a majority stake in South Africa's Cipla Medpro to strengthen its presence in Africa's fast-growing market for cheap, generic versions of branded drugs.
Source: The Economic Times Healthcare and Biotech News - November 21, 2012 Category: Pharmaceuticals Source Type: news
Diffusion completes Phase I brain cancer trial of trans sodium crocetinate
Biotechnology company Diffusion Pharmaceuticals has announced the completion of a Phase I brain cancer trial of trans sodium crocetinate (TSC) in nine patients with glioblastoma (GBM).
Source: Drug Development Technology - November 20, 2012 Category: Pharmaceuticals Source Type: news
Xoma's drug combo lowers high blood pressure in late-stage study
(Reuters) - Xoma Corp said its experimental combination of two drugs met the main goal of lowering hypertension better than a treatment based on either of the drugs alone in a late-stage study, sending the biotechnology company's shares up 6 percent.
Source: Reuters: Health - November 20, 2012 Category: Consumer Health News Tags: healthNews Source Type: news
Lupin launches generic TriCor in US
Drugmaker Lupin said that it launched a generic version of Abbott Laboratories' cholesterol lowering drug TriCor in the United States.
Source: The Economic Times Healthcare and Biotech News - November 20, 2012 Category: Pharmaceuticals Source Type: news
Study Shows Innovative ERT-Based Solution Has The Potential To Address Unmet Clinical Needs Across A Range Of Lysosomal Storage Diseases
Oxyrane, has announced the publication in Nature Biotechnology, results of its landmark study in novel enzyme replacement therapy (ERT) for lysosomal storage diseases (LSDs). Oxyrane, in collaboration with VIB researchers from Ghent University and Vrije Universiteit Brussels, have developed a new technology that enables a more efficient approach to ERT production for LSD treatments, as well as the potential to significantly improve future treatments for debilitating and often life-threatening LSDs such as Pompe disease, Fabry disease and Hunter's syndrome...
Source: Health News from Medical News Today - November 20, 2012 Category: Consumer Health News Tags: Pediatrics / Children's Health Source Type: news
Take action against GE salmon - Tell the FDA to ban it now!
It has been more than two years since the biotechnology company AquAdvantage first petitioned the U.S. Food and Drug Administration (FDA) to approve its genetically-engineered (GE) salmon AquaBounty for human consumption, and the agency still has not given the "Frankenfish...
Source: NaturalNews.com - November 20, 2012 Category: Consumer Health Advice Source Type: news
Major international push to maximize bioscience research to help world's poorest farmers
(Biotechnology and Biological Sciences Research Council) Sequencing historical DNA to tackle wheat's worst enemy. Unlocking ancient rice secrets to overcome rainfall extremes. Leaving a bad taste in aphids' mouths. Reducing crop losses with cereals that respond to pest attack. Exploiting wild wheat to produce better Indian varieties.
Source: EurekAlert! - Biology - November 20, 2012 Category: Biology Source Type: news
Fetal Bovine Serum - Australian and New Zealand Origin
TCS Biosciences is pleased to offer fetal bovine serum (FBS) of Australian and New Zealand origin, produced by Moregate BioTech.
Source: Pharmaceutical Technology - November 19, 2012 Category: Pharmaceuticals Source Type: news
Introduce market-based pricing for drugs: Assocham to govt
Assocham asked the govt to introduce a market-based pricing policy for drugs, saying it will help encourage investments in the sector and manufacturing of quality medicines.
Source: The Economic Times Healthcare and Biotech News - November 19, 2012 Category: Pharmaceuticals Source Type: news
Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial
Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, recently announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).
Source: Pharmaceutical Online News - November 19, 2012 Category: Pharmaceuticals Source Type: news
Medimmune Creating Drug Pipeline for AstraZeneca
[the Baltimore
Sun]
From Baltimore Sun (MD) (November 18, 2012)
Nov. 18--When Gail Folena-Wasserman joined Gaithersburg
biotechnology startup MedImmune in 1991, she was its first employee
in research...
Source: Drugs.com - Pharma News - November 19, 2012 Category: Pharmaceuticals Source Type: news
Dr Reddy's announces launch of Sildenafil tablets
This followed the approval by the United States Food & Drug Administration of Dr Reddy's ANDA for Sildenafil tablets, a company statement said here.
Source: The Economic Times Healthcare and Biotech News - November 19, 2012 Category: Pharmaceuticals Source Type: news
More Fowl Genetics: The Origins of the Chicken
While most of us in the United Stated spent a lot of time contemplating the turkey last week, the chicken is, of course, the most important domesticated fowl. As a matter of fact, it is the world's most common bird. Given its esteemed status, it may be surprising that there is not a lot known about it's domestication....Read Full Post
Source: About.com Biotech Biomedical - November 19, 2012 Category: Biotechnology Source Type: news
New technology for a more efficient treatment of Pompe disease and other metabolic disorders
(VIB (the Flanders Institute for Biotechnology)) VIB researchers from UGent and Vrije Universiteit Brussel, together with a team of the firm Oxyrane have developed a new technology that can lead to a more efficient and possibly also cheaper therapy for diseases such as Pompe disease. Oxyrane will now start developing a clinical program for this therapy in Pompe disease.
Source: EurekAlert! - Medicine and Health - November 19, 2012 Category: Global & Universal Source Type: news
£12 million funding to tackle devastating livestock and poultry viruses
(Biotechnology and Biological Sciences Research Council) Over £5.6M to transform the way foot and mouth disease will be controlled in the future.Over £6.2M to develop rapid responses to emerging poultry viruses.
Source: EurekAlert! - Biology - November 19, 2012 Category: Biology Source Type: news
Breakthrough selectively represses immune system: New hope for multiple sclerosis, type 1 diabetes, food allergies, and asthma
Innovative biotechnology selectively inhibits the part of the immune system responsible for attacking myelin and gives new hope to those suffering from autoimmune diseases such as multiple sclerosis, type 1 diabetes, food allergies, and asthma.
Source: ScienceDaily Headlines - November 18, 2012 Category: Science Source Type: news
Boycott the enemies of the people
By now, we all know about the Proposition 37 travesty in California. The biotech industry did what they do best - lie and deceive and the major food companies maintained their use of GMOs in their foods. What was alarming is that most of the major food companies bought...
Source: NaturalNews.com - November 18, 2012 Category: Consumer Health Advice Source Type: news
Outrageous false claim: Frankenscientists say purple medicinal 'GMO' tomatoes can beat cancer
Forget spirulina, pomegranates, blueberries, and the host of other natural "superfoods" with incredible nutritive and healing powers -- the biotechnology industry has developed a new purple "Frankentomato" that it claims can single-handedly halt inflammation, stop plaque...
Source: NaturalNews.com - November 18, 2012 Category: Consumer Health Advice Source Type: news
Research breakthrough selectively represses the immune system
(NIH/National Institute of Biomedical Imaging & Bioengineering) Innovative biotechnology selectively inhibits the part of the immune system responsible for attacking myelin and gives new hope to those suffering from autoimmune diseases such as Multiple Sclerosis, type 1 diabetes, food allergies, and asthma.
Source: EurekAlert! - Medicine and Health - November 18, 2012 Category: Global & Universal Source Type: news
Biocon to come out with new drug for treating Psoriasis
Biocon today said it will soon come out with a new drug for treating inflammatory skin disease Psoriasis as the first clinical trial of the drug has shown encouraging results.
Source: The Economic Times Healthcare and Biotech News - November 17, 2012 Category: Pharmaceuticals Source Type: news
Biocon in insulin deal with US drug major Bristol-Myers Squibb
Biocon has entered into a partnership for its oral insulin pill IN-105, giving BMS the option to exclusively develop and sell the product if the clinical trials prove successful.
Source: The Economic Times Healthcare and Biotech News - November 16, 2012 Category: Pharmaceuticals Source Type: news
Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach
The publicly-quoted Norwegian biotech Clavis Pharma ASA and its U.S. partner Clovis Oncology Inc. announced Nov. 12 the failure of their joint lead product, the potential pancreatic cancer therapy CP-4126...
Source: OncologySTAT Latest News - November 16, 2012 Category: Cancer & Oncology Source Type: news
Biocon inks pact with Bristol-Myers for insulin drug candidate IN-105
Biotechnology major Biocon today said it has entered into an agreement with Bristol-Myers Squibb for it's oral insulin new drug candidate IN-105.
Source: The Economic Times - November 16, 2012 Category: Consumer Health News Source Type: news
Biocon, Bristol-Myers in deal for oral insulin drug
MUMBAI (Reuters) - Biocon Ltd, India's top-listed biotechnology company, said it signed an agreement with Bristol-Myers Squibb Co under which the U.S. drugmaker will have the option to get the worldwide license to its oral insulin drug program.
Source: Reuters: Health - November 16, 2012 Category: Consumer Health News Tags: healthNews Source Type: news
Waxing Innovative: Researchers Pump Up Artificial Muscles Using Paraffin
When Scientific American heard from chemist Ray Baughman a year ago, he and his international team of nanotechnologists had taken artificial-muscle technology to the next level . Their innovation relied on spinning lengths of carbon nanotubes into buff yarns whose twisting and untwisting mimicked natural muscles found in an elephant's trunk or a squid's tentacles. [More]
Source: Scientific American Topic - Nanotechnology - November 15, 2012 Category: Nanotechnology Tags: Technology,Health,Physics,Consumer Electronics,Energy & Sustainability,Biotechnology,Biotechnology,Communications,Chemistry,More Science Source Type: news
Legal spends on the rise as drug cos take on global peers
The domestic pharma industry has spent 1,963 crore on legal cases and opinions so far this fiscal, a 21% increase over last year.
Source: The Economic Times Healthcare and Biotech News - November 15, 2012 Category: Pharmaceuticals Source Type: news
Biotech Intarcia Raises $210 Million
Intarcia Therapeutics said it raised $210 million, enabling the biotechnology company to fund late-stage clinical trials for a new diabetes treatment without forming an alliance with a major drug maker.
Source: WSJ.com: Health - November 15, 2012 Category: Pharmaceuticals Tags: PAID Source Type: news
Stem cell research thrives, despite patent ruling on destruction of embryos
Scientists working with stem cells have found ways to ensure their treatments can be patented and are commercially viableA ruling by the Court of Justice for the European Union at the end of last year that procedures using embryonic stem cells cannot be patented sent a shockwave through the biotechnology industry. However, one year on, human stem cell research is still thriving as it innovates to side-step the ethical issues surrounding the destruction of embryos.In fact, long before Greenpeace brought its case against the German neuroscientist, Oliver Brüstle, to the court last year, research scientists had been explorin...
Source: Guardian Unlimited Science - November 15, 2012 Category: Science Tags: Ethics Blogposts Biology Health guardian.co.uk Medical research Human biology Society Stem cells Science Source Type: news
Analysis: Sanofi lets Genzyme's biotech culture call the shots
PARIS (Reuters) - When Sanofi boss Chris Viehbacher first met staff at Genzyme, the U.S. biotech he had just acquired after a long takeover battle, he told them he did not want "planeloads of people coming from Paris over here to kind of Sanofize Genzyme".
Source: Reuters: Health - November 15, 2012 Category: Consumer Health News Tags: healthNews Source Type: news
The GM tree plantations bred to satisfy the world's energy needs
Israeli biotech firm says its modified eucalyptus trees can displace the fossil fuel industryIt's a timber company's dream but a horrific industrial vision for others: massive plantations of densely planted GM eucalyptus trees stretching across Brazil, South Africa, Indonesia and China, engineered to grow 40% faster for use as paper, as pellets for power stations and as fuel for cars.The prospect is close, says Stanley Hirsch, chief executive of the Israeli biotech company FuturaGene. All that is missing, he says, are permissions from governments for the trees to be grown commercially, and backing from conservation gr...
Source: Guardian Unlimited Science - November 15, 2012 Category: Science Authors: John Vidal Tags: Energy Biodiversity World news Biomass and bioenergy guardian.co.uk Natural resources and development Trees and forests Brazil GM Energy efficiency Energy research Plants Biofuels Energy industry Global development Environmen Source Type: news
Governor Cuomo Announces Regeneron Pharmaceuticals To Expand In The Capital Region
Governor Andrew M. Cuomo today announced that Regeneron Pharmaceuticals, Inc. will invest nearly $70 million to expand its Rensselaer County production facility and create 300 high-paying, biotech jobs in the Capital Region. Regeneron is the largest biopharmaceutical company in New York State, and the addition of 300 new biotech jobs at its East Greenbush location is the largest growth for the industry in New York State this year.
Source: Pharmaceutical Online News - November 15, 2012 Category: Pharmaceuticals Source Type: news
Analysis: Sanofi lets Genzyme's biotech culture call the shots
PARIS (Reuters) - When Sanofi boss Chris Viehbacher first met staff at Genzyme, the U.S. biotech he
had just acquired after a long takeover battle, he told them he did not want "planeloads of people coming
from Paris over here to kind of Sanofize Genzyme".
Source: Modern Medicine - November 15, 2012 Category: Journals (General) Source Type: news
bioMérieux and Quanterix Sign Strategic Partnership
Source: bioMerieux Press Releases - November 14, 2012 Category: Biotechnology Source Type: news
"Draft Sequence" of Pig Genome Could Benefit Agriculture and Medicine
T. J. Tabasco is something of a porcine goddess at the University of Illinois, Urbana-Champaign, where her ruddy, taxidermied head looks down from the office wall of geneticist Lawrence Schook. Now she has been immortalized in this week’s Nature -- not by name, but by the letters of her DNA. [More]
Source: Scientific American Topic - Biotechnology - November 14, 2012 Category: Biotechnology Tags: More Science,Health,Biotechnology,More Science,Biotechnology,Biology Source Type: news
'Draft Sequence' of Pig Genome Could Benefit Agriculture and Medicine
T. J. Tabasco is something of a porcine goddess at the University of Illinois, Urbana-Champaign, where her ruddy, taxidermied head looks down from the office wall of geneticist Lawrence Schook. Now she has been immortalized in this week’s Nature -- not by name, but by the letters of her DNA. [More]
Source: Scientific American Topic - Biotechnology - November 14, 2012 Category: Biotechnology Tags: More Science,Health,Biotechnology,Biotechnology,Biology,More Science Source Type: news
Jet Life Penny Stock Newsletter Updates Top Biotech Stock Dynavax...
http://www.jetlifepennystocks.com Newsletter Updating Investors on Dynavax Technologies and Heplisav.(PRWeb November 13, 2012)Read the full story at http://www.prweb.com/releases/dynavaxheplisav/hepatitisbvaccine/prweb10132033.htm
Source: PRWeb: Medical Pharmaceuticals - November 14, 2012 Category: Pharmaceuticals Source Type: news
TONIX Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Completes Convertible Note Offering
NEW YORK, NY (MARKET WIRE) Tonix Pharmaceuticals Holding Corp. (OTCQB: TNXP) ("TONIX" or the "Company"), a specialty pharmaceutical company developing novel treatments for challenging disorders of the central nervous system, including fibromyalgia ("FM") and post-traumatic stress disorder ("PTSD"), today reported that it has raised $710,000 in a convertible note offering. The notes bear interest at 8% and may convert into a future private placement at a 25% discount unless redeemed. The notes have a one year term and may be converted into shares of the Company's common stock at a conversion price of $1.00 per share,
Source: Market Wire - Pharmaceuticals and Biotech - November 14, 2012 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech TNXP Source Type: news
Cambridge Heart Inc.: Cambridge Heart Reports Results for the Three and Nine Months Ended September 30, 2012
TEWKSBURY, MA (MARKET WIRE) Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today reported results for the three and nine months ended September 30, 2012. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which will be filed with the Securities and Exchange Commission on November 14, 2012.
Source: Market Wire - Pharmaceuticals and Biotech - November 14, 2012 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare CAMH Source Type: news
Response Biomedical Corp.: Response Biomedical Corp. Announces Third Quarter 2012 Financial Results
VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) today reported financial results for the three and nine months ended September 30, 2012.
Source: Market Wire - Pharmaceuticals and Biotech - November 14, 2012 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare RBM RPBIF Source Type: news
Agile Therapeutics: Agile Therapeutics Commercial Head Named Bronze Stevie Winner in the 2012 Stevie(R) Awards for Women in Business
PRINCETON, NJ (MARKET WIRE) Agile Therapeutics commercial head Katie MacFarlane has been named a Bronze Stevie Winner for the Female Entrepreneur of the Year Stevie® Award in the Consumer Products, 10 or Fewer Employees category, in the Stevie Awards for Women in Business.
Source: Market Wire - Pharmaceuticals and Biotech - November 14, 2012 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech N/A Source Type: news
SmartMetric, Inc.: Biometric Safeguarded Electronic Medical Records Protected by SmartMetric Biometrics
BAY HARBOR, FL (MARKET WIRE) Is your medical privacy being protected while providing 24/7 access to your vital medical records whenever and wherever you may need them? SMARTMETRIC, INC. (OTCQB: SMME) today announces the release of an electronic medical records storage product that will allow for the capture and storage of a person's complete medical history and files giving medical care givers instant access to a patient's vital medical history. The President and CEO of SmartMetric, Inc. M/s Chaya Hendrick, speaking from the company's manufacturing center in Buenos Aires, Argentina, said today that the SmartMetric
Source: Market Wire - Pharmaceuticals and Biotech - November 14, 2012 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare SMME Source Type: news
Boston Therapeutics: Boston Therapeutics Reports Third Quarter and Nine Months 2012 Financial Results
MANCHESTER, NH (MARKET WIRE) Boston Therapeutics, Inc. (OTCQB: BTHE)
Source: Market Wire - Pharmaceuticals and Biotech - November 14, 2012 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech BTHE Source Type: news
Atossa Genetics, Inc.: Atossa Genetics, Inc. Announces Closing of Initial Public Offering
SEATTLE, WA (MARKET WIRE) Atossa Genetics, Inc. (NASDAQ: ATOS) announced today the closing of its initial public offering of 800,000 shares of its common stock at an initial public offering price of $5.00 per share. Atossa Genetics' common stock is traded on the NASDAQ Capital Market under the trading symbol "ATOS."
Source: Market Wire - Pharmaceuticals and Biotech - November 14, 2012 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare ATOS Source Type: news
Ill. Governor Quinn Announces Durata Therapeutics Moves to Chicago
Biotech Start-Up Relocates from New Jersey, Plans to Create Up
to 100 Jobs, Cites Talent Pool as Draw
CHICAGO—November 14, 2012. Governor Pat Quinn announced today
that biopharmaceutical company Durata Therapeutics is moving its
global...
Source: Drugs.com - Pharma News - November 14, 2012 Category: Pharmaceuticals Source Type: news
Governor Cuomo Announces Regeneron Pharmaceuticals to Expand in The Capital Region
Largest expansion in New York State’s biotech industry
this year will create 300 new jobs
Albany, NY (November 13, 2012) - Governor Andrew M. Cuomo today
announced that Regeneron Pharmaceuticals, Inc. will invest nearly
$70 million to expand...
Source: Drugs.com - Pharma News - November 14, 2012 Category: Pharmaceuticals Source Type: news
New Licensed Biopharmaceutical Manufactured by Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA® (ocriplasmin) in the USA for…
Source: Drug Development Technology - November 14, 2012 Category: Pharmaceuticals Source Type: news
Fujifilm Diosynth Biotechnologies Partners With Piramal Healthcare to Produce Antibody Drug Conjugates
Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing ni…
Source: Drug Development Technology - November 14, 2012 Category: Pharmaceuticals Source Type: news
